Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A.

Cell. 1996 May 31;85(5):721-32.

2.

Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K.

Cell. 1996 May 31;85(5):707-20.

3.

A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.

Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM.

Cell. 1996 May 31;85(5):733-44.

4.

Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.

Hsieh FF, Barnett LA, Green WF, Freedman K, Matushansky I, Skoultchi AI, Kelley LL.

Blood. 2000 Oct 15;96(8):2746-54.

5.

A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.

Coats S, Whyte P, Fero ML, Lacy S, Chung G, Randel E, Firpo E, Roberts JM.

Curr Biol. 1999 Feb 25;9(4):163-73.

6.

The absence of p27Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa->luteal transition.

Tong W, Kiyokawa H, Soos TJ, Park MS, Soares VC, Manova K, Pollard JW, Koff A.

Cell Growth Differ. 1998 Sep;9(9):787-94.

7.

CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.

Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y.

Genes Dev. 1998 Sep 15;12(18):2899-911.

8.

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.

Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H.

Mol Cell Biol. 1999 Oct;19(10):7011-9.

9.

p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation.

Teixeira LT, Kiyokawa H, Peng XD, Christov KT, Frohman LA, Kineman RD.

Oncogene. 2000 Apr 6;19(15):1875-84.

10.

Genetic evidence for the interactions of cyclin D1 and p27(Kip1) in mice.

Tong W, Pollard JW.

Mol Cell Biol. 2001 Feb;21(4):1319-28.

11.
12.
13.
14.

STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1).

de Koning JP, Soede-Bobok AA, Ward AC, Schelen AM, Antonissen C, van Leeuwen D, Löwenberg B, Touw IP.

Oncogene. 2000 Jul 6;19(29):3290-8.

15.

Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.

Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M, Sata M.

Hepatology. 2001 May;33(5):1087-97.

PMID:
11343236
16.
18.

Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1).

Wang G, Miskimins R, Miskimins WK.

Exp Cell Res. 2000 Jan 10;254(1):64-71.

PMID:
10623466
19.

Role of cyclin A and p27 in anti-IgM induced G1 growth arrest of murine B-cell lymphomas.

Ezhevsky SA, Toyoshima H, Hunter T, Scott DW.

Mol Biol Cell. 1996 Apr;7(4):553-64.

20.

Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors.

Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S, Shimon I.

J Endocrinol. 1998 May;157(2):337-41.

Supplemental Content

Support Center